CS
SIOX

Candriam SCA’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Candriam SCA’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-8,625
Closed -$475K – 785
2017
Q3 		$475K Sell
8,625
-3,000
-26% -$506K 0.01% 663
2017
Q2 		$2.16M Sell
11,625
-8,375
-42% -$1.47M 0.04% 446
2017
Q1 		$2.39M Buy
20,000
+8,750
+78% +$917K 0.05% 408
2016
Q4 		$1.12M Buy
+11,250
New +$1.18M 0.03% 498

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Candriam SCA's SIOX Position: Q4 2017 in Review

Candriam SCA sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2017, closing a stake of 8,625 shares — an estimated $475K sold.

Candriam SCA first reported a position in SIOX in Q4 2016 and held it in 4 quarters. The position peaked at $2.39M in Q1 2017. 104 funds tracked by Wall St. Rank hold SIOX as of Q4 2017.

  • Candriam SCA reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Candriam SCA sold 8,625 Sio Gene Therapies Inc. Common Stock shares in Q4 2017, an estimated $475K.
  • Candriam SCA first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2016 and held it in 4 quarters.
  • Candriam SCA's Sio Gene Therapies Inc. Common Stock position peaked at $2.39M in Q1 2017.
  • 104 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2017.

Based on Candriam SCA's 13F filing for Q4 2017, filed 7 Feb 2018.